Cantargia: Inclusion of AML & MDS

Research Note



We have now included acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) in our sum-of-the-parts valuation. As mentioned before, this has a minor impact on our base case, but it demonstrates the potentially broad application of anti-IL1RAP therapy, including in haematological cancers.


Richard Ramanius

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.